[Bronchial reactivity as factor of effectiveness of new antiasthmatic drugs].
To evaluate bekotid and bekodisk effects on bronchial reactivity and sensitivity. Bronchial reactivity and sensitivity were studied in a comparative study of two corticosteroids for inhalation--bekotid and bekodisk--in 37 patients with bronchial asthma. Unlike bekotid, bekodisk does not contain freon which irritates mucosa of the upper respiratory tracts and bronchi. The examination included clinical and allergological tests, provocative inhalation tests, peak flowmetry, assessment of bronchial resistance and external respiration function. Bekodisk treatment reduced the number of asphyxia episodes, sensitivity to carbacholine, the need in inhalation sympathomimetics, improved external respiration function. Determination of reactivity and sensitivity of the bronchi is essential for comparison of drugs against bronchial asthma. Bekodisk significantly lowers reactivity to nonspecific mediatory substances, is simple and available in application, is more tolerable than bekotid.